All sponsors

Transcenta Therapeutics (Hangzhou) Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING0
READOUTS ≤12 MONTHS4
Open Transcenta Therapeutics (Hangzhou) Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Denosumab
NCT07806331
P2Not yet recruitingPostmenopausal Osteoporosis; Low Bone Mass1102027-04-30
TST001
NCT04495296
P1/2Active, not recruitingAdvanced Cancer3202027-06-30 (+58 mo)
TST003
NCT05731271
P1/2Active, not recruitingLocally Advanced Solid Tumor; Metastatic Tumor1112027-06-30 (+26 mo)
TST001
NCT04396821
P1/2Active, not recruitingAdvanced Cancer; Gastric Cancer1502027-06-30 (+54 mo)
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil
NCT06093425
P3Not yet recruitingGastric Cancer; Gastroesophageal-junction Cancer8202029-10-01 (+48 mo)